Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Needham Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
09:54am, Monday, 13'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
AQR Capital Management LLC Takes $237,000 Position in Collegium Pharmaceutical Inc (NASDAQ:COLL)
08:50am, Monday, 13'th Apr 2020
AQR Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) during the fourth quarter, according to the company in its most recent 13F filing with the Securit
Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Zacks Investment Research
10:32am, Sunday, 12'th Apr 2020
Zacks Investment Research downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. Accordi
William Blair Sticks to Its Buy Rating for Albireo Pharma (ALBO)
07:37pm, Thursday, 09'th Apr 2020
In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO). The company's shares closed last Thursday at
William Blair Sticks to Its Buy Rating for Albireo Pharma (ALBO)
07:37pm, Thursday, 09'th Apr 2020
In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO – Research
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Pfenex (PFNX)
07:37pm, Thursday, 09'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY), SAGE Therapeutics (SAGE) and Pfenex (PFNX)
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), SAGE Therapeutics (NASDAQ: SAGE) and Pfenex (NYSE MKT: PFNX)
07:37pm, Thursday, 09'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (
INCY
–
Research Report
), SAGE Therapeutics (
SAGE
–
Research Report
) and Pfenex (
PFNX
�
Stock Market's Next Move
07:00pm, Thursday, 09'th Apr 2020
The market remains unsettled but is moving higher as it expects good things to happen after the hot spots peak. The impact of the pandemic will keep expanding d
Collegium Pharmaceutical Inc (NASDAQ:COLL) Shares Acquired by Goldman Sachs Group Inc.
10:00am, Thursday, 09'th Apr 2020
Goldman Sachs Group Inc. increased its stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 204.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commi
Cubist Systematic Strategies LLC Acquires Shares of 31,237 Collegium Pharmaceutical Inc (NASDAQ:COLL)
09:06am, Thursday, 09'th Apr 2020
Cubist Systematic Strategies LLC bought a new position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) in the 4th quarter, according to its most recent filing with the Securities and Exchange
Collegium to Participate in Upcoming Investor Conference
08:01pm, Tuesday, 07'th Apr 2020
STOUGHTON, Mass., April 07, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
Needham Remains a Buy on KalVista Pharmaceuticals (KALV)
05:10pm, Tuesday, 07'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
Needham Remains a Buy on KalVista Pharmaceuticals (KALV)
05:10pm, Tuesday, 07'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price
H.C. Wainwright Thinks Menlo Therapeutics' Stock is Going to Recover
11:13am, Tuesday, 07'th Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Menlo Therapeutics (MNLO) today and set a price target of $2.00. The company's shares
H.C. Wainwright Thinks Menlo Therapeutics’ Stock is Going to Recover
11:13am, Tuesday, 07'th Apr 2020
H.C. Wainwright analyst
Oren Livnat
maintained a
Buy
rating on Menlo Therapeutics (
MNLO
–
Research Report
) today and set a price target of
$2.00
. The company’s shares closed last Monday at $1.4
